Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 50c, Revenues Beat; Raises FY19 Revenue Guidance Above Consensus
Tweet Send to a Friend
Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of $0.18, $0.50 better than the analyst estimate of ($0.32). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
